AC Immune SA (ACIU) vs Palisade Bio (PALI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Palisade Bio (PALI) has outperformed AC Immune SA (ACIU) over the past year, losing 11.9% versus a loss of 28.4%. Over five years, ACIU leads with a -58.4% price change compared with -99.9% for PALI. AC Immune SA is the larger company by market cap ($253.5 million vs $252.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACIU | PALI |
|---|---|---|
| Share price | $2.55 | $1.45 |
| Market cap | $253.54M | $252.69M |
| 1-day change | -0.78% | -2.03% |
| YTD return | -18.15% | -37.02% |
| 1-year return | -28.41% | -11.90% |
| 5-year return | -58.41% | -99.93% |
| P/E ratio (TTM) | — | 2.42 |
| Forward P/E | 4.29 | — |
| EPS (TTM) | $-0.54 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.00 | $2.86 |
| 52-week low | $2.10 | $1.32 |
| Distance from 52-week high | -36.25% | -49.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +234.12% | +604.83% |
| Average volume | 202.76K | 2.60M |
| Shares outstanding | 99.43M | 174.27M |
| Employees | 90 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PALI has outperformed ACIU by 16.5 percentage points over the past year.
About AC Immune SA
ACIU stock →AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees
About Palisade Bio
PALI stock →Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 14 employees
ACIU vs PALI FAQ
Which is bigger, AC Immune SA or Palisade Bio?
AC Immune SA (ACIU) is larger, with a market capitalization of $253.54M compared with $252.69M for Palisade Bio (PALI).
Which stock has performed better over the past year, ACIU or PALI?
PALI returned -11.90% over the past 12 months, compared with -28.41% for ACIU (price return, excluding dividends). Past performance does not predict future results.
Are AC Immune SA and Palisade Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for AC Immune SA and Biotechnology: Biological Products (No Diagnostic Substances) for Palisade Bio.